GSK Denosumab Deal Gives Amgen A Leg Up In Primary Care
Executive Summary
Thanks to a new deal with GlaxoSmithKline for the marketing of its cherished bone drug denosumab outside the U.S. in post-menopausal osteoporosis, Amgen gets a much needed, solid launch pad for its first major venture into primary care
You may also be interested in...
Amgen's Prolia Gains First Regulatory Win, With Market Approval in Europe
The European Commission has finally granted a marketing authorization for Amgen's bone loss therapy, Prolia (denosumab), five months after CHMP issued a positive opinion
Amgen's Prolia Gains First Regulatory Win, With Market Approval in Europe
The European Commission has finally granted a marketing authorization for Amgen's bone loss therapy, Prolia (denosumab), five months after CHMP issued a positive opinion
Amgen's Prolia Gains First Regulatory Win: Market Approval in Europe
Amgen and GlaxoSmithKline will assume marketing responsibilities in Europe for osteoporosis, and Amgen will market it for oncology.